Article Category: Drugs

Understanding dementia 7: Developing drug treatments

Continuing our clinical teaching series, Dr Robert Tobiansky describes the many routes of current research and development in the search for a pharmacological treatment for dementia. Author/s: Robert Tobiansky For the full article please see the PDF download linked to the right. The full JDC archive is available if you subscribe....

This content is for Individual, Organisation 1 User, Organisation 2-10 Users, Organisation 11-50 Users, Organisation 51+ users, Reduced Rate, Member Subscriber - Individual, Member Subscriber - Carer or Person with Dementia , Member Subscriber - Organisation, 1 user, and Member Subscriber - Organisation, 2-10 Users members only.
Login Join Now

Understanding dementia 8: Other drugs aimed at reducing cognitive defects

Dr Robert Tobiansky describes research into use of drugs acting on non-cholinergic neurotransmitter systems. Author/s: Robert Tobiansky For the full article please see the PDF download linked to the right. The full JDC archive is available if you subscribe....

This content is for Individual, Organisation 1 User, Organisation 2-10 Users, Organisation 11-50 Users, Organisation 51+ users, Reduced Rate, Member Subscriber - Individual, Member Subscriber - Carer or Person with Dementia , Member Subscriber - Organisation, 1 user, and Member Subscriber - Organisation, 2-10 Users members only.
Login Join Now

Why be a guinea pig?

Now that Tacrine has been approved for use in France as well as the US, should you encourage people with dementia and their carers to take part in trials of other drugs? John Kellett believes there are good reasons to do so. Author/s: John Kellett For the full article please see the PDF download linked...

This content is for Individual, Organisation 1 User, Organisation 2-10 Users, Organisation 11-50 Users, Organisation 51+ users, Reduced Rate, Member Subscriber - Individual, Member Subscriber - Carer or Person with Dementia , Member Subscriber - Organisation, 1 user, and Member Subscriber - Organisation, 2-10 Users members only.
Login Join Now

Developing a drug to treat dementia

Palliative therapies are likely to precede disease-modifying agents by years or decades, but these earlydrugs will provide the tools for future medical research, writes Professor Peter Stonier. Author/s: Peter Stonier For the full article please see the PDF download linked to the right. The full JDC archive is available if you subscribe....

This content is for Individual, Organisation 1 User, Organisation 2-10 Users, Organisation 11-50 Users, Organisation 51+ users, Reduced Rate, Member Subscriber - Individual, Member Subscriber - Carer or Person with Dementia , Member Subscriber - Organisation, 1 user, and Member Subscriber - Organisation, 2-10 Users members only.
Login Join Now

Carers have different priorities

Would a drug for dementia that produced modest improvement be worth using, despite side effects? Carers’ views contrast sharply with those of professionals on this question, as Antony Bayer’s research showed. Author/s: Antony Bayer For the full article please see the PDF download linked to the right. The full JDC archive is available if you...

This content is for Individual, Organisation 1 User, Organisation 2-10 Users, Organisation 11-50 Users, Organisation 51+ users, Reduced Rate, Member Subscriber - Individual, Member Subscriber - Carer or Person with Dementia , Member Subscriber - Organisation, 1 user, and Member Subscriber - Organisation, 2-10 Users members only.
Login Join Now